Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Eylea | Aflibercept | Macular degeneration, age-related | List with criteria/condition | Complete | ||
Zaltrap | Aflibercept | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Giotrif | Afatinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse | Complete | ||
Aduhelm | aducanumab | Alzheimer’s disease | Withdrawn | |||
Hepsera | Adefovir dipivoxil | Hepatitis B | List with clinical criteria and/or conditions | Complete | ||
Hepsera | Adefovir dipivoxil | Hepatitis B | Do not list | Complete | ||
Humira | Adalimumab | Hidradenitis suppurativa | Reimburse with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
Humira | Adalimumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | ulcerative colitis | Withdrawn |